Bevacizumab and Chemotherapy for Recurrent Glioblastoma: a Single-institution Experience

Overview

Journal Neurology

Specialty Neurology

Date 2009 Apr 8

PMID 19349600

Citations 119

Authors

P L Nghiemphu

W Liu

Y Lee

T Than

C Graham

A Lai

R M Green

W B Pope

L M Liau

P S Mischel

S F Nelson

R Elashoff

T F Cloughesy

Affiliations

Soon will be listed here.

Abstract

Objective: Bevacizumab has been shown to be effective in the treatment of recurrent glioblastoma in combination with chemotherapy compared with historic controls but not in randomized trials.

Methods: We conducted a retrospective analysis of patients treated for recurrent glioblastoma with bevacizumab vs a control group of patients, comparing progression-free survival (PFS) and overall survival (OS) between the two groups, and performed subgroup analysis based on age and performance status. Expression of vascular endothelial growth factor (VEGF) based on age was examined using DNA microarray analysis. We also evaluated the impact of bevacizumab on quality of life.

Results: We identified 44 patients who received bevacizumab and 79 patients who had not been treated with bevacizumab. There was a significant improvement in PFS and OS in the bevacizumab-treated group. Patients of older age (> or =55 years) and poor performance status (Karnofsky Performance Status < or =80) had significantly better PFS when treated with bevacizumab, and bevacizumab-treated older patients had significantly increased OS. VEGF expression was significantly higher in older glioblastoma patients (aged > or =55 years). Patients treated with bevacizumab also required less dexamethasone use and maintained their functional status longer than the control group.

Conclusions: Bevacizumab in combination with chemotherapy may be a more effective treatment for recurrent glioblastoma and warrants further randomized prospective studies to determine its effect on survival. Bevacizumab also has more effect in those with older age and might reflect biologic differences in glioblastoma in different age groups as seen with the expression of vascular endothelial growth factor.

Citing Articles

Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.

Sadowski K, Jazdzewska A, Kozlowski J, Zacny A, Lorenc T, Olejarz W Int J Mol Sci. 2024; 25(11).

PMID: 38891962 PMC: 11172387. DOI: 10.3390/ijms25115774.

The complexities of treating brain and spinal cord tumors: a review of current approaches.

Mansour A, Trefi A, Mansour M, Shekho A, Salloum S Ann Med Surg (Lond). 2023; 85(10):4969-4972.

PMID: 37811056 PMC: 10552955. DOI: 10.1097/MS9.0000000000001213.

Distinct aneuploid evolution of astrocytoma and glioblastoma during recurrence.

Zhang J, Feng Y, Li G, Zhang J, Zhang X, Zhang Y NPJ Precis Oncol. 2023; 7(1):97.

PMID: 37741941 PMC: 10517995. DOI: 10.1038/s41698-023-00453-1.

Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma.

Aravantinou-Fatorou A, Georgakopoulou V, Mathioudakis N, Papalexis P, Tarantinos K, Trakas I Mol Clin Oncol. 2023; 19(3):73.

PMID: 37614373 PMC: 10442729. DOI: 10.3892/mco.2023.2669.

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map.

Fu M, Zhou Z, Huang X, Chen Z, Zhang L, Zhang J BMC Cancer. 2023; 23(1):544.

PMID: 37316802 PMC: 10265794. DOI: 10.1186/s12885-023-11043-6.

References

Vecht C, Hovestadt A, Verbiest H, van Vliet J, van Putten W . Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology. 1994; 44(4):675-80. DOI: 10.1212/wnl.44.4.675. View

Batchelor T, Sorensen A, Tomaso E, Zhang W, Duda D, Cohen K . AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11(1):83-95. PMC: 2748664. DOI: 10.1016/j.ccr.2006.11.021. View

Batchelor T, Byrne T . Supportive care of brain tumor patients. Hematol Oncol Clin North Am. 2006; 20(6):1337-61. DOI: 10.1016/j.hoc.2006.09.013. View

Day A, Carlson M, Dong J, OConnor B, Nelson S . Celsius: a community resource for Affymetrix microarray data. Genome Biol. 2007; 8(6):R112. PMC: 2394754. DOI: 10.1186/gb-2007-8-6-r112. View

Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S . Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5(10):R80. PMC: 545600. DOI: 10.1186/gb-2004-5-10-r80. View

Pope W, Lai A, Nghiemphu P, Mischel P, Cloughesy T . MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006; 66(8):1258-60. DOI: 10.1212/01.wnl.0000208958.29600.87. View

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

Vredenburgh J, Desjardins A, Herndon 2nd J, Dowell J, Reardon D, Quinn J . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13(4):1253-9. DOI: 10.1158/1078-0432.CCR-06-2309. View

Wong E, Hess K, Gleason M, Jaeckle K, Kyritsis A, PRADOS M . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8):2572-8. DOI: 10.1200/JCO.1999.17.8.2572. View

10.

Carlson M, Pope W, Horvath S, Braunstein J, Nghiemphu P, Tso C . Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res. 2007; 13(9):2592-8. DOI: 10.1158/1078-0432.CCR-06-2772. View

11.

Vredenburgh J, Desjardins A, Herndon 2nd J, Marcello J, Reardon D, Quinn J . Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25(30):4722-9. DOI: 10.1200/JCO.2007.12.2440. View

12.

Hutchins L, Unger J, Crowley J, COLTMAN Jr C, Albain K . Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341(27):2061-7. DOI: 10.1056/NEJM199912303412706. View

13.

Rich J, Hans C, Jones B, Iversen E, McLendon R, Rasheed B . Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 2005; 65(10):4051-8. DOI: 10.1158/0008-5472.CAN-04-3936. View

14.

Freije W, Castro-Vargas F, Fang Z, Horvath S, Cloughesy T, Liau L . Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004; 64(18):6503-10. DOI: 10.1158/0008-5472.CAN-04-0452. View

15.

Lamszus K, Ulbricht U, Matschke J, Brockmann M, Fillbrandt R, Westphal M . Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res. 2003; 9(4):1399-405. View

16.

Lee Y, Scheck A, Cloughesy T, Lai A, Dong J, Farooqi H . Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics. 2008; 1:52. PMC: 2596165. DOI: 10.1186/1755-8794-1-52. View

17.

Lamborn K, Yung W, Chang S, Wen P, Cloughesy T, DeAngelis L . Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008; 10(2):162-70. PMC: 2613818. DOI: 10.1215/15228517-2007-062. View

18.

Norden A, Young G, Setayesh K, Muzikansky A, Klufas R, Ross G . Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008; 70(10):779-87. DOI: 10.1212/01.wnl.0000304121.57857.38. View

19.

Phillips H, Kharbanda S, Chen R, Forrest W, Soriano R, Wu T . Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9(3):157-73. DOI: 10.1016/j.ccr.2006.02.019. View

20.

Plate K, Breier G, Weich H, Risau W . Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992; 359(6398):845-8. DOI: 10.1038/359845a0. View